← Leaderboards
Farhood Farjah
University Of Washington
$5,283,632
Attributed
$6,157,584
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,157,584 · 4
By mechanism
R01$4,353,996 · 2
U01$1,747,905 · 1
F32$55,683 · 1
Top collaborators
- Michael Scott Mulligan4 shared
Most similar at University Of Washington
Same institution · by research overlap
- Joann G Elmore$17,641,997
- Donald Lee Weaver$8,806,953
- Linda Shapiro$5,572,723
- Edward Donald Verrier$3,637,079
- Michael Scott Mulligan$3,425,510
Others in their field
Top investigators on “Cohort”
- David R. Weir · University Of Michigan At Ann Arbor$406,814,098
- George R Seage · Abt Associates, Inc.$297,656,361
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$242,146,554
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$227,738,417
- Lawrence Corey · Fred Hutchinson Cancer Center$227,738,417
- James Dennis Neaton · Northwestern University$203,539,316
Research focus
CohortPatient-Focused OutcomesInvestigationInfrastructureRisk EstimatePredictive ModelingFollow-UpRecommendationCaringCharacteristicsPractice GuidelinesHigh RiskUncertaintyReportingResearch DesignLinkDiagnosticLevel Of EvidenceAdverse EventMeasurementCancer Research NetworkEvaluationMethodologyNovel Strategies
Grant awards (13)
Comparative-Effectiveness of Pretreatment Lung Cancer Nodal Staging$601,359
R01 · FY2025 · CA · contact PI
Lung transplant recipient exosome phenotypes and the risk of primary graft dysfunction and acute lung allograft dysfunction$433,531
U01 · FY2025 · HL
Comparative-Effectiveness of Pretreatment Lung Cancer Nodal Staging$569,699
R01 · FY2024 · CA · contact PI
Lung transplant recipient exosome phenotypes and the risk of primary graft dysfunction and acute lung allograft dysfunction$423,420
U01 · FY2024 · HL
Comparative-Effectiveness of Pretreatment Lung Cancer Nodal Staging$600,635
R01 · FY2023 · CA · contact PI
Lung transplant recipient exosome phenotypes and the risk of primary graft dysfunction and acute lung allograft dysfunction$441,074
U01 · FY2023 · HL
Comparative-Effectiveness of Pretreatment Lung Cancer Nodal Staging$665,706
R01 · FY2022 · CA · contact PI
Lung transplant recipient exosome phenotypes and the risk of primary graft dysfunction and acute lung allograft dysfunction$449,880
U01 · FY2022 · HL
The Effectiveness, Safety, and Costs of Guideline-Concordant Lung Nodule Care$178,349
R01 · FY2020 · CA · contact PI
The Effectiveness, Safety, and Costs of Guideline-Concordant Lung Nodule Care$507,649
R01 · FY2019 · CA · contact PI
The Effectiveness, Safety, and Costs of Guideline-Concordant Lung Nodule Care$621,132
R01 · FY2018 · CA · contact PI
The Effectiveness, Safety, and Costs of Guideline-Concordant Lung Nodule Care$609,467
R01 · FY2017 · CA · contact PI
A Population-Based Analysis of Mediastinal Staging for Non-Small Cell Lung Cancer$55,683
F32 · FY2007 · CA · contact PI